Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955104 | 1.00 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDPPARGPPARA | |
| SCHEMBL29955154 | 0.86 | KDM4E (0.50) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL1163265 | 0.86 | KDM4E (0.50) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL30016565 | 0.84 | MKNK1 (0.48) | ALDH1A1KDM4EHPGDHTTCA1 | |
| SCHEMBL189207 | 0.84 | KDM4E (0.46) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL4814821 | 0.81 | TSHR (0.49) | ALDH1A1KDM4EHPGDTDP1HSD17B10 | |
| SCHEMBL29955699 | 0.79 | HSD17B2 (0.47) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL5058938 | 0.79 | HSD17B2 (0.47) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL5788486 | 0.79 | SMN1; SMN2 (0.64) | ALDH1A1MAPT | |
| SCHEMBL2770512 | 0.77 | ALDH1A1 (0.67) | ALDH1A1KDM4EHPGDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118957992-B | Preparation method of high-hardness crosslinked modified hydroxy acrylic resin | 莱阳红安化工有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118957992-A | Preparation method of high-hardness crosslinked modified hydroxy acrylic resin | 莱阳红安化工有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-116987319-A | Functionalized boric acid affinity material and preparation method and application thereof | 苏州赛分科技股份有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-118957992-B | Preparation method of high-hardness crosslinked modified hydroxy acrylic resin | 莱阳红安化工有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118957992-A | Preparation method of high-hardness crosslinked modified hydroxy acrylic resin | 莱阳红安化工有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-117384150-A | Thiazolidinones immunoproteasome inhibitor and its preparation method and pharmaceutical use | 中国医学科学院药物研究所 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023215514-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-116987319-A | Functionalized boric acid affinity material and preparation method and application thereof | 苏州赛分科技股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2010116282-A1 | 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100254903-A1 | Substituted Aryl-Fluoroborates as Imaging Agents | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-10-07 | — | — | US | disclosed |
| US-20100254903-A1 | Substituted Aryl-Fluoroborates as Imaging Agents | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-10-07 | — | — | US | disclosed |
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | disclosed |
| EP-2061784-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-27 | — | — | EP | disclosed |
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| WO-2008032086-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | ALDH1A1 2481/4885KDM4E 946/4885HPGD 2180/4885 |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | ALDH1A1 106/4885KDM4E 2845/4885HPGD 1970/4885 |
| US-20100254903-A1 | Substituted Aryl-Fluoroborates as Imaging Agents | SIGMAR1, AP3S1, SLC1A5 | ALDH1A1 2514/4885KDM4E 2923/4885HPGD 4390/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | ALDH1A1 638/4885KDM4E 4443/4885HPGD 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.